Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03977675 · ClinicalTrials.gov registry record · Phase 1
The Role of HNKs in the Antidepressant Effect of Ketamine
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03977675 is a Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 8 participants.
The verdict
NCT03977675, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The objective of the proposed study is to examine the relationship between serum concentrations of HNK and changes in the Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), and the Profile of Mood States (POMS), as well as glutamatergic/GABAergic response. To achieve these aims the investigators propose a double-blind, uncontrolled (no placebo, no healthy control subjects) study with several different doses of ketamine. The investigators will conduct MRI scans to measure Glu and GABA before and during the ketamine treatment.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2020-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03977675
The ClinicalTrials.gov registry entry for NCT03977675 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT03977675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03977675 about?
NCT03977675 is a clinical study titled "The Role of HNKs in the Antidepressant Effect of Ketamine". The objective of the proposed study is to examine the relationship between serum concentrations of HNK and changes in the Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), and the Profile of Mood States (POMS), as well as glutamatergic/GABAergic response. To achieve these aim...
What is the current status of trial NCT03977675?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-05-15. Estimated completion is 2020-07-02.
What interventions are being tested in trial NCT03977675?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT03977675?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.